Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

Cell

Volumn 142, Issue 5, 2010, Pages 699-713

  Chao, Mark P ^a   Alizadeh, Ash A ^a,b   Tang, Chad ^a   Myklebust, June H ^b,f   Varghese, Bindu ^b   Gill, Saar ^b   Jan, Max ^a   Cha, Adriel C ^a   Chan, Charles K ^a   Tan, Brent T ^b   Park, Christopher Y ^a,b   Zhao, Feifei ^a   Kohrt, Holbrook E ^b   Malumbres, Raquel ^c   Briones, Javier ^d   Gascoyne, Randy D ^e   Lossos, Izidore S ^c   Levy, Ronald ^b   Weissman, Irving L ^a,b   Majeti, Ravindra ^a,b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cellimmuno; Humdisease

Indexed keywords

BLOCKING ANTIBODY; CD47 ANTIBODY; CD47 ANTIGEN; FC RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENGRAFTMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; XENOTRANSPLANTATION; ANIMAL; B LYMPHOCYTE; DRUG SCREENING; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD47; B-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; LYMPHOMA, NON-HODGKIN; MICE; PHAGOCYTOSIS; RECEPTORS, FC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956150056     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2010.07.044     Document Type: Article

References (37)

1. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
2. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
3. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001, 11:130-135.
4. Cartron G., Watier H., Golay J., Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635-2642.
5. Chan K.S., Espinosa I., Chao M., Wong D., Ailles L., Diehn M., Gill H., Presti J., Chang H.Y., van de Rijn M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009, 106:14016-14021.
6. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 2008, 359:613-626.
7. Chou T.C. Preclinical versus clinical drug combination studies. Leuk. Lymphoma 2008, 49:2059-2080.
8. Daniel D., Yang B., Lawrence D.A., Totpal K., Balter I., Lee W.P., Gogineni A., Cole M.J., Yee S.F., Ross S., Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007, 110:4037-4046.
9. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358:2704-2715.
10. Foran J.M., Norton A.J., Micallef I.N., Taussig D.C., Amess J.A., Rohatiner A.Z., Lister T.A. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br. J. Haematol. 2001, 114:881-883.
11. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823-3837.
12. Hiraga J., Tomita A., Sugimoto T., Shimada K., Ito M., Nakamura S., Kiyoi H., Kinoshita T., Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113:4885-4893.
13. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
14. Jaiswal S., Chao M.P., Majeti R., Weissman I.L. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010, 31:212-219.
15. Katzenberger T., Petzoldt C., Holler S., Mader U., Kalla J., Adam P., Ott M.M., Muller-Hermelink H.K., Rosenwald A., Ott G. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.
16. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., Densmore J.J., Williams M.E., Taylor R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 2004, 172:3280-3288.
17. Kikuchi Y., Uno S., Yoshimura Y., Otabe K., Iida S., Oheda M., Fukushima N., Tsuchiya M. A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells. Biochem. Biophys. Res. Commun. 2004, 315:912-918.
18. Kikuchi Y., Uno S., Kinoshita Y., Yoshimura Y., Iida S., Wakahara Y., Tsuchiya M., Yamada-Okabe H., Fukushima N. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk. Res. 2005, 29:445-450.
19. Kim M.J., Lee J.C., Lee J.J., Kim S., Lee S.G., Park S.W., Sung M.W., Heo D.S. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol. 2008, 29:28-34.
20. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., Niesvizky R., Shore T., Chadburn A., Horne H., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 2005, 23:5044-5051.
21. Leonard J.P., Friedberg J.W., Younes A., Fisher D., Gordon L.I., Moore J., Czuczman M., Miller T., Stiff P., Cheson B.D., et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann. Oncol. 2007, 18:1216-1223.
22. Leonard J.P., Schuster S.J., Emmanouilides C., Couture F., Teoh N., Wegener W.A., Coleman M., Goldenberg D.M. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008, 113:2714-2723.
23. Maddipatla S., Hernandez-Ilizaliturri F.J., Knight J., Czuczman M.S. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin. Cancer Res. 2007, 13:4556-4564.
24. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., van Rooijen N., Weissman I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
25. Mateo V., Lagneaux L., Bron D., Biron G., Armant M., Delespesse G., Sarfati M. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat. Med. 1999, 5:1277-1284.
26. Milush J.M., Long B.R., Snyder-Cappione J.E., Cappione A.J., York V.A., Ndhlovu L.C., Lanier L.L., Michaelsson J., Nixon D.F. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 2009, 114:4823-4831.
27. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 2007, 19:239-245.
28. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., Corcoran M.M., Chapman R.M., Thomas P.W., Copplestone J.A., et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100:1177-1184.
29. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346:1937-1947.
30. Rosenwald A., Wright G., Wiestner A., Chan W.C., Connors J.M., Campo E., Gascoyne R.D., Grogan T.M., Muller-Hermelink H.K., Smeland E.B., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
31. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
32. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
33. Takai T., Li M., Sylvestre D., Clynes R., Ravetch J.V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994, 76:519-529.
34. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319:1-7.
35. Taylor R.P., Lindorfer M.A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 2008, 20:444-449.
36. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993, 329:987-994. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
37. Uno S., Kinoshita Y., Azuma Y., Tsunenari T., Yoshimura Y., Iida S., Kikuchi Y., Yamada-Okabe H., Fukushima N. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol. Rep. 2007, 17:1189-1194.